Post-Hemorrhagic Anemia Treatment Market - Growth Drivers and Challenges
Growth Drivers
- Rising Cases of Blood Disorders– Hemophilia is a genetic blood condition that hinders the healthy clotting and coagulation of blood. Therefore, patients require frequent blood transfusion as a part of their treatment. Moreover, in the United States, around 18,400 people were diagnosed with hemophilia in the year 2021. Furthermore, around 10,000 people are suffering with other bleeding disorders.
- Rising Incidents of Accidents– Accidents can cause severe injuries and lead to heavy blood loss; therefore, timely control of blood loss is an absolute necessity. According to the World Health Organization, every year around 1.3 million people die de to vehicle crash and in other road accidents. Moreover, over 50% of deaths on road is attributed to pedestrian, cyclists, and motorcyclists. In addition to this, road accidents are the primary cause of death for people between the age 5 to 29 years.
- Rise in the Number of Surgical Procedures – Surgery involves massive blood loss that is likely to boost the demand for post-hemorrhagic anemia treatment. Around 40 to 50 million major procedures are performed annually in the USA, and about 20 million in Europe, for a startling total of nearly 310 million worldwide.
- Rising Cases of Heart Patient– Heart patients are usually prescribed blood thinning medicines that increases the chances of post-hemorrhagic anemia. In the world, around 550 million people suffer from heart issues and circulation disorders. These problems are usually caused by unhealthy lifestyle & eating habits, and ageing population. Moreover, nearly 60 million people all over the world develops the heart disease, each year. This count is almost equal to entire population of the United Kingdom.
- A Family History of Anemia – A person with anemia is already in deficiency of red blood cells and it can even worsen the situation in the case of post-hemorrhagic anemia. Therefore, post hemorrhagic anemia treatment can be used in aplastic anemia treatment, sickle-cell anemia treatment, and others. According to World Health Organization statistics, anemia affects 40% of pregnant women and 42% of children under the age of five worldwide.
Challenges
- Shortage of skilled workers – A patient suffering from post-hemorrhagic anemia can die if not handled under the immediate expert professionals. Therefore, lack of skilled workers is expected to hamper the market growth.
- A lack of some medical therapies' accessibility
- Lack of treatment awareness in certain under-developed regions
Post-Hemorrhagic Anemia Treatment Market Size and Forecast:
|
Base Year |
2025 |
|
Forecast Year |
2026-2035 |
|
CAGR |
5.9% |
|
Base Year Market Size (2025) |
USD 6.15 billion |
|
Forecast Year Market Size (2035) |
USD 10.91 billion |
|
Regional Scope |
|
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2026, the industry size of post-hemorrhagic anemia treatment is estimated at USD 6.48 billion.
The global post-hemorrhagic anemia treatment market size was around USD 6.15 billion in 2025 and is likely to expand at a CAGR of more than 5.9%, surpassing USD 10.91 billion revenue by 2035.
By 2035, North America is expected to capture a 36% share of the post-hemorrhagic anemia treatment market, underpinned by rising hospital admissions and strengthened healthcare infrastructure investment.
Key players in the market include Rockwell Medical, Inc., Amgen Inc., Vifor Pharma Management Ltd., F. Hoffmann-La Roche Ltd, Pfizer Inc., Novartis AG, Teva Pharmaceutical Industries Ltd., Johnson & Johnson Services, Inc., AMAG Pharmaceuticals, Akebia Therapeutics.
